Citizens Maintains Market Outperform on Compass Therapeutics, Lowers Price Target to $4
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Citizens analyst Reni J. Benjamin maintains Compass Therapeutics (NASDAQ:CMPX) with a Market Outperform and lowers the price target from $10 to $4.
Citizens analyst Reni J. Benjamin maintains Compass Therapeutics (NASDAQ:CMPX) with a Market Outperform and lowers the price target from $10 to $4.